MedWatch

Leo Pharma expands its arsenal of arguments for Adtralza with new long-term data

While Leo Pharma is in full swing with getting eczema treatment Adtralza onto the market, and is anxiously waiting on US approval, the company has presented new long-term data for the drug, causing excitement.

Photo: Leo Pharma / PR

Leo Pharma has been developing the medicine tralokinumab for so long that it can now present data for the treament stretching over two years. The drug was already approved earlier this year as a treatment for atopic dermatitis in the EU under the name Adtralza.

The company's new data was presented at the conference for the European Academy of Dermatology and Venereology (EADV), and according to Vice President at Leo Pharma Bo Bang, Leo Pharma now has an ace up its sleeve.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs